美股新聞 標題聯播 · 近 24 小時 248 則 · 31 個來源 · 最新 9/20 02:59
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · RVMD近 30 天 12 則 · 第 1 / 1 頁
- Revolution Medicines’ (RVMD) Promising Clinical Results Signal Potential Paradigm Shift
- Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc.
- Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
- Revolution Medicines (RVMD) Gets its First Approved Drug, and the Market Shrugs
- Revolution Medicines Got a ‘Miracle’ Cancer Drug Approval. Wall Street Wants More.
- Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
- Revolution Medicines (RVMD) Wins FDA Nod While Cancer Study Lands In Leading Journal
- Revolution Med (RVMD) Priced Rasonque at $39,800 per 30-Day Supply. Can Access Match the Clinical Breakthrough?
- Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
- Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
- Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer
- New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
- Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。